R3i Foundation

Welcome to the official YouTube channel of the R3i Foundation (Residual Risk Reduction Initiative).

We are a global academic initiative advancing awareness of residual vascular risk—driven by elevated remnant cholesterol, triglyceride-rich lipoproteins, and other non-LDL factors.

Expert interviews, conference highlights, and summaries of key publications from literature provide the latest clinical evidence on ASCVD, diabetes, dyslipidemia, and cardiometabolic risk.

The R3i Foundation is accredited by the American Accreditation Commission International (AACI), a leader in healthcare accreditation. AACI has certified R3i’s medical content from 2020 to 2027.

🔬 Follow us for science-based insights backed by peer-reviewed studies and major trials.
🧠 For healthcare professionals, researchers, and anyone interested in preventive cardiology and lipid science.

📖 Learn more at https://r3i.org
📰 Browse our latest publications: https://r3i.org/recent-publications-on-residual-risk

Pemafibrate to Treat & Prevent Diabetic Foot Ulceration: An Unmet Clinical Need Requiring Evaluation
Pemafibrate to Treat & Prevent Diabetic Foot Ulceration: An Unmet Clinical Need Requiring Evaluation
Avances Recientes en la Farmacoterapia de la Retinopatía Diabética en DM tipo 2: Agonistas de PPARɑ.
Avances Recientes en la Farmacoterapia de la Retinopatía Diabética en DM tipo 2: Agonistas de PPARɑ.
What is their relevance to residual macrovascular risk when LDL-C is low?
What is their relevance to residual macrovascular risk when LDL-C is low?
Webinar: Recent Advances in Pharmacotherapy of Diabetic Retinopathy in Type 2 Diabetes Mellitus.
Webinar: Recent Advances in Pharmacotherapy of Diabetic Retinopathy in Type 2 Diabetes Mellitus.
Guidelines for dyslipidemia management of type 2 diabetes – new directions?
Guidelines for dyslipidemia management of type 2 diabetes – new directions?
Advances in diabetes and vascular cognitive impairment.
Advances in diabetes and vascular cognitive impairment.
Novel targets: Does PCSK7 have potential in NAFLD?
Novel targets: Does PCSK7 have potential in NAFLD?
Residual stroke risk in type 2 diabetes: what can we learn from the trials.
Residual stroke risk in type 2 diabetes: what can we learn from the trials.
New insights: PPARα/SPPARMα, stroke and dementia.
New insights: PPARα/SPPARMα, stroke and dementia.
Residual stroke risk in T2D – insights from trials. Does SPPARMα have therapeutic potential?
Residual stroke risk in T2D – insights from trials. Does SPPARMα have therapeutic potential?
Emerging glucose-lowering therapies in type 2 diabetes: insights from the trials.
Emerging glucose-lowering therapies in type 2 diabetes: insights from the trials.
Understanding protective effects in diabetic kidney disease: from biomarkers to clinical outcomes.
Understanding protective effects in diabetic kidney disease: from biomarkers to clinical outcomes.
Reducing cardiovascular risk in type 2 diabetes by glucose lowering – does the drug matter?
Reducing cardiovascular risk in type 2 diabetes by glucose lowering – does the drug matter?
Is liver fat the nexus between diabetic dyslipidemia and CVD?
Is liver fat the nexus between diabetic dyslipidemia and CVD?
What can we learn from the PROMINENT trial?
What can we learn from the PROMINENT trial?
Understanding NAFLD: novel molecular insights.
Understanding NAFLD: novel molecular insights.
PROMINENT and PROMINENT Substudy: Rationale and Update.
PROMINENT and PROMINENT Substudy: Rationale and Update.
Overview of clinical trials with pemafibrate in Japan and Europe.
Overview of clinical trials with pemafibrate in Japan and Europe.
Non-alcoholic fatty liver disease, dyslipidemia and CVD: is liver fat the critical link?
Non-alcoholic fatty liver disease, dyslipidemia and CVD: is liver fat the critical link?
New therapeutic targets in lipids and atherosclerosis: exploring the pipeline.
New therapeutic targets in lipids and atherosclerosis: exploring the pipeline.
How do we interpret the results of PROMINENT? What does it mean for clinical practice?
How do we interpret the results of PROMINENT? What does it mean for clinical practice?
New insights into the metabolism and atherogenicity of TG-rich lipoproteins and their remnants.
New insights into the metabolism and atherogenicity of TG-rich lipoproteins and their remnants.
New pathways linking cholesterol efflux to inflammasome activation.
New pathways linking cholesterol efflux to inflammasome activation.
TG-rich lipoproteins and their remnants: why are they atherogenic and how best to assess this?
TG-rich lipoproteins and their remnants: why are they atherogenic and how best to assess this?
Can changes in lifestyle impact residual vascular risk?
Can changes in lifestyle impact residual vascular risk?
Targeting cholesterol: what is new?
Targeting cholesterol: what is new?
Insights from the 2nd International Steering Committee meeting.
Insights from the 2nd International Steering Committee meeting.
Triglyceride-rich lipoproteins and remnant cholesterol: unmet clinical needs.
Triglyceride-rich lipoproteins and remnant cholesterol: unmet clinical needs.
Molecular and clinical insights of diabetic retinopathy.
Molecular and clinical insights of diabetic retinopathy.
Emerging target: PCSK7
Emerging target: PCSK7